Laryngeal Tumors Research Articles

Endobronchial laryngeal tumor “embolus”creating respiratory difficulty during surgery: A case report

Unusual laryngeal and tracheobronchial obstructing lesions are seen on occasion [1-3]. A patient was evaluated by his primary physician and pulmonologist due to symptoms referable to his chest including a cough and shortness of breath. Evaluation, including lexible bronchoscopy, revealed a primary carcinoma of the left upper lobe of the long.

Schwannoma of False Vocal Cord - A Rare Entity

Laryngeal Schwannoma is rare comprising 0.1 – 1.5% of all benign laryngeal tumors. The most common site in larynx is aryepiglottic fold followed by arytenoids, ventricular folds, and vocal cord. Patients present with the symptoms of hoarseness, dysphagia or globus sensation. We present a 33-year-old male with supraglottic schwannoma who experienced hoarseness of voice for three months. The patient underwent micro laryngeal surgery and submucosal solid tumor of false vocal cord was removed. Postoperative recovery was uneventful and after one month of follow up the patient was improving with no hoarseness of voice.

Rose Bengal and Future Directions in Larynx Tumor Photodynamic Therapy.

Photodynamic Therapy (PDT) seems to be a promising method in the treatment of larynx tumor tissues. The aim of the present analysis was the study of photosensitizer penetration of larynx tissue associated with the application of PDT invitro. This study is based on the use of photosensitive compounds Rose Bengal (RB) that selectively accumulate in larynx tissue. The selection of the study group of patients who will undergo surgery in accordance with medical principles was of key importance for the project. Histopathological examination of samples subjected to PDT revealed numerous changes in the morphology of the cancer cells and surrounding tissues. After PDT treatment, the number of tumor cells decreased compared with the cells number before PDT and the arrangement was relatively loose. After PDT with RB the nuclei morphology was incomplete and fragmented. The effects of the applied PDT of larynx invitro were assessed under an optical microscope. The future directions in larynx tumor PDT with the use of upconversion nanoparticles (UPCNP) is also discussed.

Serum hypoxia-inducible factor-2: A candidate prognostic biomarker for laryngeal cancer.

To determine the serum hypoxia-inducible factor-1, -2 and -3 (HIF-1, -2 and -3) levels in patients with laryngeal neoplasm, and to investigate their role in differential diagnosis, prediction of tumour characteristic and extension, and prognosis and survival. Prospective, cohort study at a tertiary referral centre. The study was conducted in a tertiary medical centre. Patients with benign, premalignant and malignant laryngeal neoplasms were included. Sixty-four patients with a laryngeal neoplasm were enrolled. Serum HIF-1, -2 and -3 levels were measured from blood samples that were drawn before treatment, using ELISA. A statistically significant difference between benign (HIF-1, -2, -3:4046,1pg/mL; 2581,5pg/mL; 1321,0pg/mL), premalignant (HIF-1, -2, -3:3630,3pg/mL; 3229,7pg/mL; 2549,8pg/mL) and malignant (HIF-1, -2, -3:3576,7pg/mL; 2595,8pg/mL; 1106,3pg/mL) laryngeal neoplasms was not detected when serum HIF-1, -2 and -3 levels were compared. However, high serum HIF-2 level adversely affected survival and locoregional control and had more than 7-fold increase in hazard ratio. Moreover, serum HIF-2 was an independent prognostic factor for 2-year overall, disease-free, distant metastasis-free survival and locoregional control. This is the first clinical study in which the diagnostic, predictive and prognostic roles of hypoxia-related biomolecules were examined in laryngeal neoplasms. Hypoxia-inducible factor-2 is a prognostic factor in larynx cancer irrespective of treatment modality.

Laryngeal Cancer With Lung Metastases Showing Long-Term Complete Response and Delayed Immune-Related Adverse Event After Nivolumab Discontinuation.

We report a case of laryngeal cancer with multiple lung metastases that maintained a complete response (CR) for 18 months after discontinuing nivolumab treatment, with colitis developing 5 months after drug discontinuation. A 65-year-old man was diagnosed with T3N2cM0 stage IVA right supraglottic squamous cell carcinoma that progressed after 1 course of TPF (cisplatin, docetaxel, and 5-fluorouracil) as induction chemotherapy. He underwent total laryngectomy, bilateral neck dissection, pharyngeal reconstruction with anterolateral thigh flap, and creation of a permanent tracheostoma; extranodal extension was detected in the right cervical lymph node metastasis, and the patient underwent adjuvant radiotherapy. Multiple lung metastases occurred during radiotherapy, and the patient was deemed platinum refractory; nivolumab treatment was thus initiated. The tumor proportion score for programmed death-ligand 1-evaluated via antibody testing of the laryngeal tumor-was <1. The patient received 240 mg/body nivolumab every 2 weeks; a computed tomography performed after course 16 of nivolumab treatment confirmed a CR. He exhibited grade 2 thyroid dysfunction, grade 1 interstitial pneumonia, and grade 2 colitis after 6, 7, and 14 months of receiving nivolumab, respectively; treatment was discontinued as despite maintaining a CR, interstitial pneumonia occurred twice. Colitis appeared 5 months after nivolumab discontinuation; nevertheless, a CR was maintained after 18 months.

Severe Snoring in a Young Healthy Female: A Diagnostic Surprise.

Laryngeal Inflammatory myofibroblastic tumors or plasma cell granulomas are unusual benign lesions. Subglottic laryngeal lesions of various benign and malignant types usually present with acute or chronic stridor and respiratory obstruction features. We describe the first case in the literature where severe snoring was the presenting complaint in a patient of subglottic mass lesion with comfortable breathing during wake hour. A 28years old female presented with loud snoring and apneic episodes during sleep for three years which showed severe Obstructive Sleep Apnoea (OSA) (AHI, Apnoea- Hypoapnoea Index: 46.5) in polysomnography (PSG) and surprisingly smooth mucosa covered subglottic mass blocking 75% of airway lumen in the laryngoscopic examination. The patient underwent tracheostomy and coblation assisted endoscopic excision, and subsequent histopathology revealed an inflammatory myofibroblastic tumour. She was later decannulated and with no features of sleep apnea post decannulation. Subglottic mass can rarely present with severe snoring and requires solid clinical suspicion for early diagnosis. Hence, subglottic lesion should be one of the differentials for atypical presentations of severe OSA.

Expression of Programmed Death Receptor 1 (PD-1) Gene and Its Ligand (PD-L1) in Patients with Laryngeal Cancer.

(1) Background: The interaction of the programmed death receptor (PD-1) with its ligand 1 (PD-L1) allows cancer cells to escape from the control of the immune system. Research evaluating the expression of immune checkpoint genes in the tissues of laryngeal tumors may contribute to the introduction of new effective immunotherapeutic methods in this group of neoplasms. The aim of this study was to evaluate the expression of the gene for the programmed death receptor (PD-1) and its ligand (PD-L1) in laryngeal tumors (T1, T2, T3) in patients without lymph node involvement and distant metastases. (2) Methods: The study included 73 patients: 39 of them were diagnosed with carcinoma planoepiteliale keratodes (study group) and 34 with nasal septal deviation undergoing septoplasty (control group). Biological material for molecular tests (Real time PCR) was collected during surgical procedures. Furthermore, all study participants completed a questionnaire regarding, among others, smoking and body weight. (3) Results: Gene expression for programmed death receptor 1 (PD-1) and its ligand 1 (PD-L1) was, statistically, significantly higher (p < 0.0001) in tumor tissue than in unchanged mucosa. Moreover, it was found that the greater the tumor size, the higher the expression level of the tested molecules. (4) Conclusions: Although further research on the role of the PD-1/PD-L1 pathway in laryngeal tumors is necessary, the presented reports are promising and may constitute a contribution to considerations on the introduction of targeted immunotherapy with anti-PD1 and anti-PD-L1 monoclonal antibodies in the treatment of these tumors.

A pilot study reveals the potential of miR-31-3p and miR-196a-5p as non-invasive biomarkers in advanced laryngeal cancer

Recently, miRNAs have become popular molecules used as non-invasive biomarkers in cancer diseases. The aim of the study was to explore the expression of four miRNAs isoforms: miR-31-3p, miR-196a-5p, miR-210-3p and miR-424-5p in plasma and tissue samples from patients with advanced laryngeal squamous cell carcinoma (LSCC) and healthy controls. Fresh-frozen tumour and normal laryngeal tissue as well as plasma samples were obtained from 22 patients diagnosed with advanced LSCC. The control group included plasma samples from 21 cancer-free volunteers. Total RNA (including miRNAs) extraction, reverse transcription and real time qPCR were the laboratory techniques used in the study. The obtained results were analyzed using SPSS software v. 23. We found that miR-31-3p, miR-196a-5p, and miR-210-3p levels were significantly elevated in laryngeal tumour tissue, but only the levels of miR-31-3p and miR-196a-5p were significantly upregulated in the plasma LSCC target group. Positive correlation was obtained for miR-31-3p (rs=0.443, p=0.039) and miR-196a-5p (rs=0.548; p=0.008) between plasma and adjacent tumour tissue LSCC samples. ROC analyses were used to evaluate the discriminative power of both miRNAs alone and in combination. The combination of miR-31-3p and miR-196a-5p showed best results with AUC=0.978 (95% CI: 0.945-1.000, p.

Modular Approach to Open Partial Horizontal Laryngectomy: Step-by-Step Anatomic Dissection.

Open partial laryngectomies still play an important role in contemporary conservative management of laryngeal cancer. A comprehensive and systematic classification of open partial horizontal laryngectomies (OPHLs) was presented by the European Laryngological Society working committee in 2014. The aim of this video is to show the main surgical steps in OPHL using a cadaveric dissection and to explain the modular approach for removal of laryngeal tumors.

The Proteomic Landscape of Growth Factor Signaling Networks Associated with FAT1 Mutations in Head and Neck Cancers.

FAT1 is frequently mutated in head and neck squamous cell carcinoma (HNSCC), but the biological and clinical effects of FAT1 mutations in HNSCC remain to be fully elucidated. We investigated the landscape of altered protein and gene expression associated with FAT1 mutations and clinical outcomes of patients with HNSCC. FAT1 mutation was stratified with clinical information from The Cancer Genome Atlas HNSCC databases with more than 200 proteins or phosphorylated sites. FAT1 mutation was significantly more prevalent among HPV(-), female, and older patients and was enriched in oral, larynx, and hypopharynx primary tumors. FAT1 mutation was also significantly associated with lower FAT1 gene expression and increased protein expression of HER3_pY1289, IRS1, and CAVEOLIN1. From an independent International Cancer Genome Consortium dataset, FAT1 mutation in oral cancer co-occurred with top mutated genes TP53 and CASP8. Poorer overall survival or progression-free survival was observed in patients with FAT1 mutation or altered HER3_pY1289, IRS1, or CAVEOLIN1. Pathway analysis revealed dominant ERBB/neuregulin pathways linked to FAT1 mutations in HNSCC, and protein signature panels uncovered the heterogeneity of patient subgroups. Decreased pEGFR, pHER2, and pERK and upregulated pHER3 and HER3 proteins were observed in two FAT1 knockout HNSCC cell lines, supporting that FAT1 alterations lead to altered EGFR/ERBB signaling. In squamous cancers of the lung and cervix, a strong association of FAT1 and EGFR gene expressions was identified. Collectively, these results suggest that alteration of FAT1 appears to involve mostly HPV(-) HNSCC and may contribute to resistance to EGFR-targeted therapy. SIGNIFICANCE: Integrative bioinformatics and statistical analyses reveal a panel of genes and proteins associated with FAT1 mutation in HNSCC, providing important insights into prospective clinical investigations with targeted therapies.

A RARE VARIANT OF SQUAMOUS CELL CARCINOMA: SARCOMATOID CARCINOMA

Background Sarcomatoid carcinoma (SC) is a rare variant of squamous cell carcinoma (SCC). It is a malignant tumor containing an SCC (in situ or invasive) component and a predominantly sarcomatous component with malignant spindle and/or pleomorphic cells. It accounts for less than 1% of all laryngeal tumors. Case Report An 8 × 5 mm polypoid lesion on the right vocal cord of a 72-year-old man with a history of smoking who presented with hoarseness was excised. In microscopic examination of the excision material, a tumoral lesion consisting highly pleomorphic cells with large nuclei and prominent nucleoli that had a spindle cell morphology in some places, an epithelioid cell morphology in some areas, and occasionally a giant cell morphology was observed. The tumor surface had an ulcerous appearance in most areas. There were typical and atypical mitoses in the tumor. Although squamous epithelium in intact benign appearance was in an area on the tumor surface, the presence of squamous epithelium containing atypical cells with disrupted organization standing apart from the tumor was remarkable. Immunohistochemical analysis revealed positive staining with smooth muscle actin and vimentin in the tumor cells. Multifocal positive staining with Pan-CK, EMA, and P40 was observed in the squamous epithelium and lesion. CD34 and desmin were negative. The case was reported to be compatible with SC. Conclusions SC is a rare variant of SCC. In the differential diagnosis, many tumors in spindle cell-like appearance such as nodular fasciitis, spindle cell melanoma, leiomyosarcoma, rhabdomyosarcoma, fibrosarcoma, synovial sarcoma, and malignant peripheral nerve sheath tumors should be kept in mind and examined carefully. Sarcomatoid carcinoma (SC) is a rare variant of squamous cell carcinoma (SCC). It is a malignant tumor containing an SCC (in situ or invasive) component and a predominantly sarcomatous component with malignant spindle and/or pleomorphic cells. It accounts for less than 1% of all laryngeal tumors. An 8 × 5 mm polypoid lesion on the right vocal cord of a 72-year-old man with a history of smoking who presented with hoarseness was excised. In microscopic examination of the excision material, a tumoral lesion consisting highly pleomorphic cells with large nuclei and prominent nucleoli that had a spindle cell morphology in some places, an epithelioid cell morphology in some areas, and occasionally a giant cell morphology was observed. The tumor surface had an ulcerous appearance in most areas. There were typical and atypical mitoses in the tumor. Although squamous epithelium in intact benign appearance was in an area on the tumor surface, the presence of squamous epithelium containing atypical cells with disrupted organization standing apart from the tumor was remarkable. Immunohistochemical analysis revealed positive staining with smooth muscle actin and vimentin in the tumor cells. Multifocal positive staining with Pan-CK, EMA, and P40 was observed in the squamous epithelium and lesion. CD34 and desmin were negative. The case was reported to be compatible with SC. SC is a rare variant of SCC. In the differential diagnosis, many tumors in spindle cell-like appearance such as nodular fasciitis, spindle cell melanoma, leiomyosarcoma, rhabdomyosarcoma, fibrosarcoma, synovial sarcoma, and malignant peripheral nerve sheath tumors should be kept in mind and examined carefully.

INCIDENTAL EXTENSIVE THYROID MALIGNANCY IN A LARYNGECTOMY FOR SQUAMOUS CARCINOMA: A CASE REPORT

<h3>Introduction</h3> Laryngectomy specimens for extensive squamous cell carcinoma (SCC) often include thyroid for both access and staging. Occasionally, incidental pathology is discovered within this tissue or the associated neck structures. We present a case of unexpected extensive thyroid malignancy, concurrent with squamous carcinoma. <h3>Clinical Presentation</h3> A 56-year-old man presented to Ear, Nose, and Throat with a 4-month history of hoarseness and palpable neck masses. He had previously suffered from follicular non-Hodgkin lymphoma, treated with bendamustine and rituximab. Following a past assault, he sustained brain damage and required tracheostomy. He was a previous smoker. A computed tomography scan revealed a supraglottic mass, subsequently confirmed as moderately differentiated SCC on microlaryngoscopic biopsy. <h3>Histopathology</h3> A total laryngectomy with bilateral modified neck dissections was performed. On sectioning, a bilateral tumor was present within the anterior supraglottis and glottis, destroying the anterior thyroid cartilage and involving the strap muscles. The included right thyroid lobectomy contained a number of pale nodules, which were sampled extensively. Histology confirmed the laryngeal tumor to be moderately differentiated SCC. The thyroid gland contained numerous foci of invasive papillary thyroid carcinoma that, at one point, collided with the SCC. The selective neck dissections contained numerous bilateral deposits of both squamous and papillary thyroid carcinoma with extracapsular extension. <h3>Conclusions</h3> Laryngeal resection specimens include numerous adjacent anatomical structures, removed both for surgical and staging purposes. Our case report highlights that these adjacent structures can include additional incidental primary disease, making careful macroscopic dissection and description vital to ensure both correct staging and to avoid second pathologies being overlooked.

High-flow nasal oxygen for laryngeal tumor debulking: case report and current challenges

&lt;p class="abstract"&gt;High-flow nasal oxygen (HFNO) has brought new opportunities in shared airway surgery. Contemporary challenges with its use in severely obstructive conditions such as laryngeal tumors still need to be addressed as there is discrepancy in its use and access among centres. We reported a case in which the use of HFNO allowed laryngeal tumor debulking while avoiding tracheotomy in a stridulous patient. The patient described was a 70 year old patient with stridor at rest secondary to a laryngeal tumor diagnosed five days before surgery. Tumor debulking could be safely initiated under general anaesthesia, which would not have been possible without HFNO. This report served as an example of an alternative to awake tracheotomy in the management of severely obstructive laryngeal pathology We wish to discuss through this case management of severely obstructive laryngeal pathology in the era of HFNO, while encouraging discussion on its potential benefits and limits.&lt;/p&gt;

Laryngeal Chondrometaplasia.

Laryngeal chondrometaplasia (LCM) is a rare clinically asymptomatic entity with reported incidence in autopsy studies of 1-2% only. Foci of metaplastic cartilage seen on histology need to be distinguished from other benign cartilaginous tumours of larynx. We present a case of LCM in an elderly male adequately managed by microlaryngeal surgery (MLS).

Association of tumor volume and outcomes in T3 larynx cancer with organ preservation approach.

e18044 Background: Organ preservation approaches to treatment of locally advanced larynx cancers are widely used and consist of radiotherapy (RT) with or without concurrent systemic therapy (CRT). Analyses of the National Cancer Database point to decreasing survival as CRT became widely adopted in place of total laryngectomy (TL). Tumor volume in T3 laryngeal tumors has been postulated as one variable to explain this finding, with higher volume associated with lower local control based on small sample size studies largely in pre-intensity modulated radiotherapy (IMRT) era, and low volume T3 tumors being associated with improved local control with CRT. We sought to validate these findings in a contemporary cohort of T3 larynx patients treated with IMRT. Methods: This was a national, multicentre retrospective cohort study of patients diagnosed with American Joint Committee on Cancer (AJCC) T3 N0-3 M0 glottic and supraglottic cancers who underwent curative intent IMRT with or without systemic treatment from 2002-2018. Tumor volumes were calculated using a validated standardized approach by a Neuroradiologist. Primary predictor was tumor volume, primary outcome was local control (LC), and secondary outcomes included overall survival (OS), as well as late grade 3+ toxicities. Kaplan Meier estimates and log-rank tests were used for survival analyses, with Cox proportional hazards used for univariable analyses. Results: 246 patients met inclusion criteria, 147 glottic and 99 supraglottic cancers. At baseline, glottic patients were more likely to be male (p &lt; 0.01), have a fixed vocal cord (p &lt; 0.01), not have pre-epiglottic space invasion ( &lt; 0.01), be cN0 (p &lt; 0.01), and have lower grade tumors (p &lt; 0.01). Mean tumor volumes for glottic and supraglottic tumors were 5.0 (4.2-5.8) cc and 13.0 (10.3–15.6) cc respectively. Univariable analysis showed systemic therapy was associated with improved local failure (HR 0.49, 95%CI 0.24 – 0.99, p = 0.05). Within the glottic cohort, tumor volume was not associated with local failure (HR 1.09, 95%CI 0.71 – 1.67, p = 0.38), however having a local failure event was associated with increased feeding tube dependence (HR 2.52, 95%CI 1.05 – 6.02, p = 0.04). Median local failure free survival in the overall cohort was 28.5 months, with median OS 23.2 months. There was a trend towards improved local control in the supraglottic cohort compared to glottic patients (log-rank p = 0.08), but the supraglottic cohort had significantly worse overall survival (log-rank p = 0.02). Conclusions: In this retrospective cohort study, there were baseline and outcome differences between patients with T3 glottic and supraglottic larynx cancer, with worse overall survival in supraglottic patients. Tumor volume was not associated with local control in the glottic cohort. These findings are pending further validation in a larger cohort and will be analyzed separately for supraglottic tumors.

The role of imaging in the evaluation of hoarseness: A review.

Hoarseness is a common symptom indicating an abnormal change in the quality of voice and has a lifetime prevalence of around 30%. There are multiple causes of hoarseness, ranging from acute laryngitis, chronic laryngitis, laryngopharyngeal reflux, functional dysphonia due to vocal overuse or abuse, vocal cord paralysis (VCP), to various pathologies and masses in the larynx. A detailed history and thorough physical examination, and in many cases, laryngoscopy by a clinician are the initial steps in its management. Laryngoscopy should be considered if hoarseness persists for more than 2 weeks without a known benign cause. An Ear Nose and Throat surgeon performs direct visualization by laryngoscopy to rule out VCP or a lesion in the larynx, and it should be performed before ordering any imaging. CT with contrast is the imaging of choice to evaluate the laryngeal tumors and find the etiology of VCP. Typical findings of VCP are ipsilateral dilatation of the pyriform sinus and laryngeal ventricle, thickening and medialization of the ipsilateral aryepiglottic fold, medialization of the arytenoid cartilage and posterior aspect of the true vocal cord (TVC) atrophy of the TVC, and loss of the subglottic arch. The lesions causing the VCP may extend from the medulla, jugular foramen, carotid space, and upper mediastinum. CT neck must cover the aorticopulmonary window when evaluating the left VCP to cover the left recurrent laryngeal nerve's origin.

Evaluation of level I neck nodes involvement in advanced malignancy of the larynx and the hypopharynx

BackgroundAdvanced cancer larynx and hypopharynx has high potentiality to nodal spread. Level of lymph node metastasis highly depends on site and stage of laryngopharyngeal carcinoma. Level I cervical lymph node dissection was performed to advanced laryngeal and/or hypopharyngeal tumors in this study.ResultsAccording to our statistical analysis and data, none of those thirty patients had pathologically positive level I neck lymph nodes after dissection with only one patient suffered from marginal mandibular nerve affection and three patients complained of dry mouth post-operatively, confirming the result that there is no need for prophylactic level I neck dissection in the absence of clinically palpable suspicious lymph nodes.ConclusionAlthough it carries relative low morbidity, there is no need for prophylactic level I neck dissection in advanced laryngeal and/or hypopharyngeal cancer patients without clinically detectable nodal metastases “N0 neck.”

Organ Preservation in Patients With Advanced Laryngeal Tumours. Results of Induction Chemotherapy Versus Chemoradiotherapy in Actual Clinical Practice

Introduction and objectivesA high percentage of patients with locally advanced laryngeal carcinoma are candidates for inclusion in organ preservation protocols. The aim of this study was to compare in actual clinical practice the results of two preservation schemes, induction chemotherapy versus chemoradiotherapy, in patients with locally advanced laryngeal carcinoma. MethodsRetrospective study conducted in 157 patients with locally advanced laryngeal tumours (T3-T4) treated with induction chemotherapy (n=121) or chemoradiotherapy (n=36). ResultsOf the 121 patients who started treatment with induction chemotherapy, 6 died as a result of toxicity, 37 were treated with surgery, and 78 completed the preservation scheme; 36 patients were treated with chemoradiotherapy. There was no significant difference in specific survival at 5 years according to whether the patients had started treatment with either induction chemotherapy or chemoradiotherapy (68.9% versus 75.7%, P=.259). A total of 45.9% of the patients achieved preservation of laryngeal function. There was a tendency for patients treated with chemotherapy to achieve laryngeal dysfunction-free survival at 5 years, which was higher than the patients treated with induction chemotherapy (55.6% versus 44.8%, P=.079). ConclusionThe patients included in a preservation protocol achieved 45.9% laryngeal dysfunction-free survival at 5 years. No significant difference in specific survival was observed between patients treated with induction chemotherapy or chemoradiotherapy.

Primary T-cell non-Hodgkin's lymphoma of the larynx: A case report

Lymphoma is a malignant disease of lymphatic cells. Despite numerous sub-types, the disease is generally divided into two main groups: Hodgkin and non-Hodgkin lymphoma. Primary laryngeal non-Hodgkin lymphoma accounts for less than 1% of all laryngeal tumors. We herein present a 43-year-old male patient with difficulty swallowing due to a laryngeal mass. Morphological and immunohistochemical examination revealed T cell lymphoma according to the World Health Organization classification. The patient was referred for chemo-radiotherapy. Primary lymphoma of the larynx is a rare, and primary T-cell laryngeal lymphoma is an even rarer tumor.

Case report of Laryngeal Amyloidosis: Unusual cause of hoarseness

Background: Laryngeal amyloidosis is a rare pathology of the airway in which the diagnosis can only be made via tissue biopsy. We reported a case of laryngeal amyloidosis presenting with symptoms of hoarseness and voice fatigue.Case report: This is a case report of laryngeal amyloidosis in a middle-aged female patient who presented with hoarseness of voice. Upon obtaining a further history and performing a clinical examination, it was noted that the patient had a laryngeal mass. She underwent surgery, and the mass was histopathologically confirmed as laryngeal amyloidosis. She was successfully treated with a combination of surgical and medical treatment. This case presentation describes these rare pathological findings, their clinical manifestations, the histopathological and surgical diagnostic problems, treatment and patient’s progress that we followed up till presence.Conclusion: Isolated laryngeal amyloidosis is a rare benign laryngeal tumor that is often presented with various symptoms depending on the tumor location and can even cause upper airway obstruction. It is a histological diagnosis confirmed by histopathological specimens that are stained with Congo red. Treatment of laryngeal amyloidosis includes symptomatic relief, surgical or even conservative treatment.Â